$CRIS
Curis Inc Stock $cris

$cris Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-Q Financial Statement

#000110820517000012 Filed on August 03, 2017

Income Statement

Concept	2017 Q3	2017 Q2	2016 Q2
Revenue	$2.444M	$2.061M	$1.680M
YoY Change	38.94%	22.68%	-19.35%
Cost Of Revenue	$120.0K	$100.0K	$100.0K
YoY Change	-99.34%	0.0%	0.0%
Gross Profit	$2.320M	$1.970M	$1.590M
YoY Change	-114.22%	23.9%	-19.7%
Gross Profit Margin	94.93%	95.58%	94.64%
Selling, General & Admin	$3.410M	$3.820M	$3.440M
YoY Change	-27.14%	11.05%	0.88%
% of Gross Profit	146.98%	193.91%	216.35%
Research & Development	$13.38M	$11.26M	$8.822M
YoY Change	97.35%	27.58%	341.1%
% of Gross Profit	576.81%	571.32%	554.84%
Depreciation & Amortization	$70.00K	$50.00K	$60.00K
YoY Change	40.0%	-16.67%	50.0%
% of Gross Profit	3.02%	2.54%	3.77%
Operating Expenses	$13.38M	$11.26M	$8.822M
YoY Change	97.35%	27.58%	341.1%
Operating Profit	-$14.47M	-$13.11M	-$10.68M
YoY Change	-47.93%	22.74%	44.93%
Interest Expense	$1.109M	$1.119M	$729.0K
YoY Change	68.8%	53.5%	-13.52%
% of Operating Profit
Other Income/Expense, Net	-$986.0K	-$981.0K	-$610.0K
YoY Change	77.34%	60.82%	-19.63%
Pretax Income	-$15.46M	-$14.09M	-$11.29M
YoY Change	-45.47%	24.8%	38.87%
Income Tax
% Of Pretax Income
Net Earnings	-$15.46M	-$14.09M	-$11.29M
YoY Change	-45.47%	24.8%	38.89%
Net Earnings / Revenue	-632.45%	-683.65%	-672.02%
Basic Earnings Per Share
Diluted Earnings Per Share	-$527.6K	-$489.9K	-$436.8K
COMMON SHARES
Basic Shares Outstanding	143.9M shares	143.8M shares	129.2M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q3	2017 Q2	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$69.20M	$51.00M	$61.70M
YoY Change	29.59%	-17.34%	-37.8%
Cash & Equivalents	$49.84M	$26.68M	$8.643M
Short-Term Investments	$19.40M	$24.40M	$53.00M
Other Short-Term Assets	$1.400M	$1.200M	$1.000M
YoY Change	0.0%	20.0%	25.0%
Inventory
Prepaid Expenses
Receivables	$2.456M	$2.231M	$1.869M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$73.00M	$54.38M	$64.52M
YoY Change	28.86%	-15.7%	-36.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$384.0K	$426.0K	$451.0K
YoY Change	-5.42%	-5.54%	39.58%
Goodwill	$8.982M	$8.982M	$8.982M
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.000K	$3.000K	$3.000K
YoY Change	0.0%	0.0%	-95.14%
Total Long-Term Assets	$9.369M	$9.411M	$9.589M
YoY Change	-1.83%	-1.86%	0.73%
TOTAL ASSETS
Total Short-Term Assets	$73.00M	$54.38M	$64.52M
Total Long-Term Assets	$9.369M	$9.411M	$9.589M
Total Assets	$82.37M	$63.80M	$74.10M
YoY Change	24.44%	-13.91%	-33.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.519M	$8.202M	$3.875M
YoY Change	28.94%	111.66%	62.45%
Accrued Expenses	$2.528M	$2.480M	$2.012M
YoY Change	8.78%	23.26%	10.67%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.116M	$3.931M	$5.429M
YoY Change	0.24%	-27.59%	12.02%
Total Short-Term Liabilities	$14.16M	$14.61M	$11.32M
YoY Change	13.45%	29.14%	25.04%
LONG-TERM LIABILITIES
Long-Term Debt	$37.76M	$39.95M	$16.54M
YoY Change	139.0%	141.57%	-24.1%
Other Long-Term Liabilities	$0.00	$0.00	$62.00K
YoY Change	-100.0%	-100.0%	-60.89%
Total Long-Term Liabilities	$37.76M	$39.95M	$16.60M
YoY Change	138.39%	140.67%	-24.37%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.16M	$14.61M	$11.32M
Total Long-Term Liabilities	$37.76M	$39.95M	$16.60M
Total Liabilities	$51.92M	$54.57M	$27.92M
YoY Change	83.32%	95.46%	-9.94%
SHAREHOLDERS EQUITY
Retained Earnings	-$944.2M	-$928.8M	-$859.3M
YoY Change	6.38%	8.09%	4.85%
Common Stock	$976.2M	$939.5M	$906.9M
YoY Change	5.31%	3.6%	0.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.524M	$1.524M	$1.524M
YoY Change	0.0%	0.0%	0.0%
Treasury Stock Shares	1.223M shares	1.223M shares	1.223M shares
Shareholders Equity	$30.45M	$9.228M	$46.19M
YoY Change
Total Liabilities & Shareholders Equity	$82.37M	$63.80M	$74.10M
YoY Change	24.44%	-13.91%	-33.58%

Cashflow Statement

Concept	2017 Q3	2017 Q2	2016 Q2
OPERATING ACTIVITIES
Net Income	-$15.46M	-$14.09M	-$11.29M
YoY Change	-45.47%	24.8%	38.89%
Depreciation, Depletion And Amortization	$70.00K	$50.00K	$60.00K
YoY Change	40.0%	-16.67%	50.0%
Cash From Operating Activities	-$16.48M	-$9.220M	-$10.85M
YoY Change	117.41%	-15.02%	59.79%
INVESTING ACTIVITIES
Capital Expenditures	-$20.00K	-$80.00K	-$250.0K
YoY Change	100.0%	-68.0%
Acquisitions
YoY Change
Other Investing Activities	$4.960M	-$5.940M	$5.370M
YoY Change	-75.49%	-210.61%	-65.86%
Cash From Investing Activities	$4.930M	-$6.010M	$5.130M
YoY Change	-75.62%	-217.15%	-67.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	34.71M	-510.0K	-320.0K
YoY Change	-5698.39%	59.38%	-65.22%
NET CHANGE
Cash From Operating Activities	-16.48M	-9.220M	-10.85M
Cash From Investing Activities	4.930M	-6.010M	5.130M
Cash From Financing Activities	34.71M	-510.0K	-320.0K
Net Change In Cash	23.16M	-15.74M	-6.040M
YoY Change	92.68%	160.6%	-175.31%
FREE CASH FLOW
Cash From Operating Activities	-$16.48M	-$9.220M	-$10.85M
Capital Expenditures	-$20.00K	-$80.00K	-$250.0K
Free Cash Flow	-$16.46M	-$9.140M	-$10.60M
YoY Change	117.44%	-13.77%	56.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	cris	Cash Distribution Paidto Parent Company CashDistributionPaidtoParentCompany	26600000	USD
CY2017Q1	cris	Cash Distribution Paidto Parent Company CashDistributionPaidtoParentCompany	26600000	USD
CY2015Q4	cris	Collaborative Arrangement Numberof Optional Additional Terms CollaborativeArrangementNumberofOptionalAdditionalTerms	3	term
CY2015Q4	cris	Collaborative Arrangement Option Fees Numberof Payments CollaborativeArrangementOptionFeesNumberofPayments	2	payment
CY2015	cris	Collaborative Arrangement Option Fees Total CollaborativeArrangementOptionFeesTotal	7500000	USD
CY2015	cris	Collaborative Arrangement Optional Additional Term CollaborativeArrangementOptionalAdditionalTerm	P1Y
CY2017Q2	cris	Numberof Oncology Drug Candidates NumberofOncologyDrugCandidates	2	candidate
	cris	Share Based Compensation Plans ShareBasedCompensationPlans	2	plan
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001108205
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	143878955	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	CURIS INC
	dei	Trading Symbol TradingSymbol	CRIS
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5883000	USD
CY2017Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	8202000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2459000	USD
CY2017Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2231000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-9000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	49000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2725000	USD
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2480000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	157000	USD
CY2017Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	220000	USD
CY2016Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2026000	USD
CY2017Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1900000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4000	USD
CY2017Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	639000	USD
CY2017Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	51000000	USD
CY2017Q2	us-gaap	Assets Assets	63795000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	48201000	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	54384000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	928319000	USD
CY2017Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	938083000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-100000	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1890000	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	5463000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	24000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	128000	USD
CY2016Q4	us-gaap	Assets Assets	57752000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	USD
CY2017Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	6000	USD
CY2017Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	18451000	USD
CY2017Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	24368000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	18447000	USD
CY2017Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	24365000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33091000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8643000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26038000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26677000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-24448000	USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	142346871	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	145101801	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	141124025	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	143878955	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	1423000	USD
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	1451000	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11293000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20702000	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14087000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29831000	USD
CY2016Q2	us-gaap	Costs And Expenses CostsAndExpenses	12360000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	22893000	USD
CY2017Q2	us-gaap	Costs And Expenses CostsAndExpenses	15170000	USD
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
	us-gaap	Interest Expense InterestExpense	1468000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	32353000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	90000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	113000	USD
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2017Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	11500000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3443000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7059000	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3819000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7351000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	8982000	USD
CY2017Q2	us-gaap	Goodwill Goodwill	8982000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-346000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2056000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-237000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-228000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-196000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-299000	USD
CY2016Q2	us-gaap	Interest Expense InterestExpense	729000	USD
CY2017Q2	us-gaap	Interest Expense InterestExpense	1119000	USD
	us-gaap	Interest Expense InterestExpense	1775000	USD
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	194000	USD
CY2017Q2	us-gaap	Interest Payable Current InterestPayableCurrent	192000	USD
CY2016Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	119000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	224000	USD
CY2017Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	138000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	208000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	28486000	USD
CY2017Q2	us-gaap	Liabilities Liabilities	54567000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	57752000	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	63795000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13547000	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	14613000	USD
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4939000	USD
CY2017Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	3931000	USD
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	14921000	USD
CY2017Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	39954000	USD
CY2016Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	18447000	USD
CY2017Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	24365000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-1443000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	31002000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-4164000	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	104000	USD
CY2017Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-5994000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-18841000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-24369000	USD
CY2016Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-11290000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-20731000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-14090000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-29832000	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-10680000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-19487000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13109000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-28161000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	348000	USD
CY2017Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	168000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3000	USD
CY2017Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	18000	USD
CY2017Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-610000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1244000	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-981000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1671000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	192000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	48744000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	27476000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	256000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	126000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1257000	USD
CY2017Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	958000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6214000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	698000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	890000	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	45000000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	44836000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	21608000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	413000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	426000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	2141000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	2607000	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	0	USD
CY2017Q2	us-gaap	Revenues Revenues	2061000	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	18303000	USD
	us-gaap	Revenues Revenues	4192000	USD
CY2016Q2	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	-162000	USD
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	-180000	USD
CY2017Q2	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	-41000	USD
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	-102000	USD
CY2016Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	8822000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	15650000	USD
CY2017Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	11255000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	24795000	USD
CY2016Q4	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	0	USD
CY2017Q2	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	153000	USD
CY2016Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	153000	USD
CY2017Q2	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	0	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-898948000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-928779000	USD
CY2016Q2	us-gaap	Revenues Revenues	1680000	USD
	us-gaap	Revenues Revenues	3406000	USD
CY2016Q2	us-gaap	Royalty Expense RoyaltyExpense	95000	USD
	us-gaap	Royalty Expense RoyaltyExpense	184000	USD
CY2017Q2	us-gaap	Royalty Expense RoyaltyExpense	96000	USD
	us-gaap	Royalty Expense RoyaltyExpense	207000	USD
CY2016Q2	us-gaap	Royalty Revenue RoyaltyRevenue	1842000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	3586000	USD
CY2017Q2	us-gaap	Royalty Revenue RoyaltyRevenue	2102000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	4294000	USD
CY2016Q2	us-gaap	Share Based Compensation ShareBasedCompensation	908000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1680000	USD
CY2017Q2	us-gaap	Share Based Compensation ShareBasedCompensation	1585000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2688000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.70
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.64
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.69
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.63
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.018
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.021
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.014
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.020
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	7986527	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.59
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	900000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	417753	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5913000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.07
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	675335	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.53
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	29266000	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	18572069	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.30
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	9228000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y0M5D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2200000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2100000	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1651000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13752157	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.39
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	2.39
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1590000	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	17590685	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.38
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.90
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.53
CY2017Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	823000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y2M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M10D
CY2016Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1222846	shares
CY2017Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	1222846	shares
CY2016Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1524000	USD
CY2017Q2	us-gaap	Treasury Stock Value TreasuryStockValue	1524000	USD
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	129270639	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	129142989	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	143786705	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	142904144	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Nature of Business</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Curis, Inc. is a biotechnology company seeking to develop and commercialize innovative drug candidates for the treatment of human cancers. As used throughout these consolidated financial statements, the term “the Company” refers to the business of Curis, Inc. and its wholly owned subsidiaries, except where the context otherwise requires, and the term “Curis” refers to Curis, Inc.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company conducts its research and development programs both internally and through strategic collaborations. The Company’s clinical stage drug candidates are CUDC-907, which is being investigated in clinical studies in patients with diffuse large B-cell lymphoma and solid tumors and CA-170, which is being investigated in a Phase 1 study in patients with advanced solid tumors and lymphomas. The Company’s pipeline includes </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> pre-Investigational New Drug, or IND, stage oncology drug candidates, CA-327 and CA-4948. The Company’s drug Erivedge® (vismodegib) is approved for the treatment of advanced basal cell carcinoma, or BCC. The Company is party to a collaboration with F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, under which Roche and Genentech are commercializing Erivedge, a first-in-class orally-administered small molecule Hedgehog signaling pathway inhibitor. In addition to BCC, Roche and Genentech are investigating Erivedge in myelofibrosis.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2015, and as amended in September 2016, the Company entered into an exclusive collaboration, option and license agreement focused on immuno-oncology and selected precision oncology targets with Aurigene Discovery Technologies Limited, or Aurigene.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The collaboration with Aurigene is comprised of multiple programs, and Curis has the option to exclusively license each program, including data, intellectual property and compounds associated therewith, once a development candidate is nominated within such program. In October 2015, the Company exercised options to license the first </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> programs under this collaboration. The first licensed program is in the immuno-oncology field and the Company has named CA-170, an orally-available small molecule antagonist of two immune checkpoints, programmed death ligand-1 (PDL1) and V domain Ig suppressor of T cell activation (VISTA), as the development candidate from this program. CA-170 is currently in Phase 1 clinical testing. The second licensed program is in the precision oncology field and the Company has named CA-4948, an orally-available small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4), as the development candidate. In October 2016, the Company exercised its option to license a third program in the collaboration, and designated CA-327, a distinct orally available small molecule antagonist of two immune checkpoints, PDL1 and T-cell immunoglobulin and mucin domain containing protein-3 (TIM3), as the development candidate from this program. The Company expects to file IND applications with the United States Food and Drug Administration, or FDA, for clinical testing of CA-4948 in the third quarter of 2017 and CA-327 in first quarter of 2018.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in a single reportable segment, which is the research and development of innovative cancer therapeutics. The Company expects that any products that are successfully developed and commercialized would be used in the health care industry and would be regulated in the United States by the FDA and in overseas markets by similar regulatory authorities.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to risks common to companies in the biotechnology industry as well as risks that are specific to the Company’s business, including, but not limited to: the Company’s ability to advance and expand its research and development programs; the Company’s reliance on Aurigene to successfully discover and preclinically develop drug candidates under the parties’ collaboration agreement; the Company’s reliance on Roche and Genentech to successfully commercialize Erivedge in the approved indication of advanced BCC and to progress its clinical development in indications other than BCC; the Company’s ability to obtain adequate financing to fund its operations; the ability of the Company and its wholly owned subsidiary, Curis Royalty, LLC, or Curis Royalty, to satisfy the terms of its credit agreement with HealthCare Royalty Partners III, L.P., a Delaware limited partnership managed by Healthcare Royalty Management, LLC, or HealthCare Royalty; the Company’s ability to obtain and maintain necessary intellectual property protection; development by the Company’s competitors of new or better technological innovations; dependence on key personnel; the Company’s ability to comply with regulatory requirements; and the Company’s ability to execute on its overall business strategies.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s future operating results will largely depend on the progress of drug candidates currently in its development pipeline and the magnitude of payments that it may receive and makes under its current and potential future collaborations. The results of the Company’s operations may vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to: the timing, outcome and cost of the Company’s preclinical studies and clinical trials for its drug candidates; Aurigene’s ability to successfully discover and develop preclinical programs under the Company’s collaboration with Aurigene, as well as the Company’s decision to exclusively license and further develop programs under this collaboration; Roche and Genentech’s ability to successfully commercialize Erivedge; and positive results in Roche and Genentech’s ongoing clinical trials.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has incurred losses and negative cash flows from operations since its inception. As of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had an accumulated deficit of approximately </font><font style="font-family:inherit;font-size:10pt;">$928.8 million</font><font style="font-family:inherit;font-size:10pt;">. The Company anticipates that its </font><font style="font-family:inherit;font-size:10pt;">$51.0 million</font><font style="font-family:inherit;font-size:10pt;"> of existing cash, cash equivalents and investments at </font><font style="font-family:inherit;font-size:10pt;">June 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> should enable it to maintain its planned operations into 2018. In order to ensure adequate cash resources for 12 months from the issuance date of these financial statements, the Company will reduce or delay spending on its research and development programs and operating expenses to the extent it is unable to raise additional financing through its current </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> at-the-market sale agreement with Cowen and Company, LLC, or Cowen or other potential financing. Accordingly, the inability to obtain additional funds in the next 12 months would have a negative impact on the Company’s financial condition and ability to pursue its business strategies. The Company’s ability to raise additional funds will depend on financial, economic and market conditions, many of which are outside of its control, and it may be unable to raise financing when needed, or on terms favorable to the Company.</font></div></div>

Files In Submission

Name	View Source	Status
0001108205-17-000012-index-headers.html	Edgar Link	pending
0001108205-17-000012-index.html	Edgar Link	pending
0001108205-17-000012.txt	Edgar Link	pending
0001108205-17-000012-xbrl.zip	Edgar Link	pending
cris-20170630.xml	Edgar Link	completed
cris-20170630.xsd	Edgar Link	pending
cris-20170630_cal.xml	Edgar Link	unprocessable
cris-20170630_def.xml	Edgar Link	unprocessable
cris-20170630_lab.xml	Edgar Link	unprocessable
cris-20170630_pre.xml	Edgar Link	unprocessable
cris-6302017x10q2.htm	Edgar Link	pending
cris-6302017x10qexx311.htm	Edgar Link	pending
cris-6302017x10qexx312.htm	Edgar Link	pending
cris-6302017x10qexx321.htm	Edgar Link	pending
cris-6302017x10qexx322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
updatedpipeline06302017.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRIS
Curis Inc Stock $cris

2017 Q3 Form 10-Q Financial Statement

#000110820517000012 Filed on August 03, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS Curis Inc Stock $cris

2017 Q3 Form 10-Q Financial Statement

#000110820517000012 Filed on August 03, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS
Curis Inc Stock $cris